NYU halted eight studies and dismissed investigator Alexander Neumeister, MD, after the FDA warned of violations in those trials, many of which were testing a fatty acid amide hydrolase inhibitor in patients with psychiatric illness. (New York Times)
GW Pharma reported positive top-line phase III results for its cannabinoid drug Epidiolex in Lennox-Gastaut syndrome, with a significant reduction in monthly frequency of drop seizures when added to current therapy over 14 weeks compared with placebo (44% versus 22%, P=0.0135). The company previously reported good top-line results in Dravet syndrome, and is also investigating the drug in tuberous sclerosis complex and infantile spasms. (Press release)
Biogen and AbbVie's once-monthly multiple sclerosis drug daclizumab (Zinbryta) got the go-ahead from European regulators. It was approved in the U.S. in May. (Press release)
There's no link between gadolinium exposure and parkinsonism, according to a research letter in JAMA.
Can a genetic "on-off" switch for agony eventually lead to promising pain drugs? (STAT News)
Improved in vitro microglia? Three separate groups at a joint neuroscience symposium in Keystone, Colo., reported creating induced pluripotent stem cell-derived microglia. Initial findings suggest a more authentic look and feel than currently available options. (AlzForum)
NeuroBreak: NYU Psych Trials Halted; Epidiolex Scores Again
Aucun commentaire:
Enregistrer un commentaire